## ACTIVITY IN 2012

(Unaudited data)

- CUMULATIVE ACTIVITY AS OF THE END OF DECEMBER 2012

| thousands of euros | 2011 | 2012 | Variation at current exchange rates | Variation at constant exchange rates |
| :---: | :---: | :---: | :---: | :---: |
| France | 292,181 | 325,900 | +11.5\% | +11.5\% |
| International: | 231,034 | 240,394 | +4.1\% | +2.4\% |
| Incl. Europe excluding France | 185,014 | 184,489 | -0.3\% | -0.8\% |
| Incl. North America | 38,416 | 45,345 | +18.0\% | +9.6\% |
| Incl. Other countries | 7,604 | 10,560 | +38.9\% | +41.0\% |
| Group Total | 523,215 | 566,294 | +8.2\% | +7.5\% |
|  |  |  |  |  |
| thousands of euros | 2011 | 2012 | Variation at current exchange rates | Variation at constant exchange rates |
| Non-proprietary Homeopathic Medicines | 265,636 | 292,025 | +9.9\% | +9.6\% |
| OTC Specialties | 257,748 | 273,776 | +6.2\% | +5.1\% |
| Other | -0,169 | 0,493 |  |  |
| Group Total | 523,215 | 566,294 | +8.2\% | +7.5\% |

- QUARTERLY ACTIVITY IN 2012 (variation at current rate)

|  | 1st Quarter |  |  | 2nd Quarter |  |  | 3rd Quarter |  |  | 4th Quarter |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| thousands of euros | 2011 | 2012 | Var. | 2011 | 2012 | Var. | 2011 | 2012 | Var. | 2011 | 2012 | Var. |
| France | 70,466 | 74,188 | +5.3\% | 59,744 | 71,210 | +19.2\% | 79,943 | 88,028 | +10.1\% | 82,028 | 92,474 | +12.7\% |
| International : | 58,478 | 54,904 | -6.1\% | 37,128 | 41,216 | +11.0\% | 67,885 | 69,839 | +2.9\% | 67,543 | 74,435 | +10.2\% |
| Incl. Europe excluding France | 47,024 | 41,807 | -11.1\% | 28,880 | 28,889 | +0.0\% | 55,013 | 55,345 | +0.6\% | 54,097 | 58,448 | +8.0\% |
| Incl. North America | 9,566 | 10,285 | +7.5\% | 6,113 | 9,861 | +61.3\% | 11,077 | 11,136 | +0.5\% | 11,660 | 14,063 | +20.6\% |
| Incl. Other countries | 1,888 | 2,812 | +48.9\% | 2,135 | 2,466 | +15.5\% | 1,795 | 3,358 | +87.1\% | 1,786 | 1,924 | +7.7\% |
| Group Total | 128,944 | 129,092 | +0.1\% | 96,872 | 112,426 | +16.1\% | 147,828 | 157,867 | +6.8\% | 149,571 | 166,909 | +11.6\% |
|  |  | st Quarter |  |  | nd Quarte |  |  | rd Quarte |  |  | th Quarter |  |
| thousands of euros | 2011 | 2012 | Var. | 2011 | 2012 | Var. | 2011 | 2012 | Var. | 2011 | 2012 | Var. |
| Non-proprietary Homeopathic Medicines | 69,371 | 73,427 | +5.8\% | 62,414 | 70,206 | +12.5\% | 63,246 | 69,959 | +10.6\% | 70,605 | 78,433 | +11.1\% |
| OTC Specialties | 59,417 | 55,576 | -6.5\% | 34,499 | 42,007 | +21.8\% | 84,645 | 87,811 | +3.7\% | 79,187 | 88,382 | +11.6\% |
| Other | 0,156 | 0,089 |  | -0,041 | 0,213 |  | -0,063 | 0,097 |  | -0,221 | 0,094 |  |
| Group Total | 128,944 | 129,092 | +0.1\% | 96,872 | 112,426 | +16.1\% | 147,828 | 157,867 | +6.8\% | 149,571 | 166,909 | +11.6\% |

## FOURTH QUARTER HIGHLIGHTS

- Sales revenue in the fourth quarter of 2012 grew by $11.6 \%$ ( $10.6 \%$ at constant exchange rates):
- In France, sales of non-proprietary medicines increased by $16.3 \%$ due to price increases applied to some of them.
- OTC specialties increased, especially in France, Poland, Russia and the US, particularly through the winter OTC specialties.
- In the United States, the settlement agreement signed on March 6, 2012 which shall put an end to all current class action proceedings (with the exception of the claim relating to Children's Coldcalm ${ }^{\circledR}$ ) obtained final approval of the San Diego Court in its judgment dated October 31, 2012. Appeals were filed against this judgment which admissibility is under consideration by the Court of Appeal.
- On December 17, 2012, the company "Pierre Fabre SA" sold its shareholding in BOIRON ( $3,330,436$ shares) to the benefit of some members of the BOIRON family group for $1,289,593$ shares and of the company BOIRON itself for $2,040,843$ shares within the frame of the applicable share buyback program. The shares acquired by the company BOIRON were cancelled on January 1, 2013 in accordance with the Board of Directors' decision dated December 19, 2012.
- At December 31, 2012, the group's net cash position exceeded 90 million euros.

Operating income in 2012 is expected to increase significantly as compared to 2011.

[^0]
[^0]:    Our next update: March 13, 2013, after the close of the stock market, publication of 2012 results.
    Financial information manager: Philippe MONTANT
    Contact for financial information: Véronique BOUSCAYROL
    Investor relations: +33 (0) 4.78.45.63.43-e-mail: finances@boiron.fr
    ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
    The group's financial information is online at : www.boiron.com

